TITLE

LONG TERM FOLLOW UP OF UC PATIENTS TREATED WITH CYCLOSPORWI--7 YEAR EXPERIENCE

AUTHOR(S)
Campbell, S.; Jewell, D. P.
PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cyclosporin (CyA) Rx has emerged as an important agent for rescue Rx in acute severe ulcerative colitis. High 1 year relapse rates advocate a limited role of this treatment in light of CyAs s/e profile. Some advocate CyA only as a stopgap to surgical Rx. There are few data available on longer follow up of these patients. These tong term data confirm efficacy and safety of CyA , since 42% patients retain their colon after 80 weeks f/u. Oral CyA appears to be at least as efficacious as intravenous CyA.
ACCESSION #
13218819

 

Related Articles

  • Digestive Disease Week 2011: An Update on IBD Clinical Research. Hoentjen, Frank // Inflammatory Bowel Disease Monitor;2011, Vol. 12 Issue 1, p42 

    Information about several papers discussed at a meeting held May 7-10, 2011 sponsored by University of Chicago Department of Medicine on biological therapy for inflammatory bowel disease (IBD) is presented. Topics include immunosuppressive therapy for patients with Crohn's disease, the use of...

  • Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy Rojas-Feria, Maria; Eslam, Mohammed; Castro-Fernández, Manuel; Guerrero, Pedro; Larraona-Moreno, Jose-Luis; Romero-Gómez, Manuel // Journal of Crohn's & Colitis;Dec2011, Vol. 5 Issue 6, p608 

    Abstract: Introduction: Biologics are generally safe and well tolerated. However, the risk of haematopoietic cancer in patients with inflammatory bowel disease receiving infliximab has been a growing concern. Case presentation: We report the first case of cutaneous lymphoma after short use of...

  • Acute Severe Colitis: Infliximab and/or Cyclosporine? Fabro, Mauro; Szabo, Hajnalka; Terrosu, Giovanni; Avellini, Claudio; Tabuso, Maria; Fiorino, Gionata; Sorrentino, Dario // Current Drug Targets;Sep2011, Vol. 12 Issue 10, p1448 

    Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality...

  • Cyclosporin for Severe Ulcerative Colitis: A User's Guide. Kornbluth, Asher; Present, Daniel H.; Lichtiger, Simon; Hanauer, Stephen // American Journal of Gastroenterology;Sep1997, Vol. 92 Issue 9, p1424 

    Discusses the administration of cyclosporin for the treatment of ulcerative colitis. Conditions of patients who can be treated with cyclosporin; Information on administering intravenous cyclosporin therapy; Use of monoclonal radioimmunoassay in monitoring cyclosporin levels.

  • Mucosal Healing and anti TNFs in IBD. Assche, Gert van; Vermeire, S�verine; Rutgeerts, Paul // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p227 

    Mucosal healing has been incorporated in the assessment of treatment efficacy in ulcerative colitis, but in Crohn's disease this concept has only emerged after biological therapies have been evaluated in clinical trials. Systemic steroids don't induce mucosal healing in Crohn's disease, but...

  • Surgical Approach to Ulcerative Colitis: When is the Best Timing after Medical Treatment? Spinelli, Antonino; Sampietro, Gianluca M.; Bazzi, Piero; Sacchi, Matteo; Montorsi, Marco // Current Drug Targets;Sep2011, Vol. 12 Issue 10, p1462 

    Ulcerative colitis (UC) is a chronic inflammatory condition of the mucosa affecting the rectum and extending up the colon in a continuous manner. Its etiology is unknown, but is most probably the result of the interaction of genetic and environmental factors. Approximately 30% of UC patients...

  • Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis. Jáuregui-Amézaga, Aránzazu; Ricart, Elena; Panés, Julián // Current Drug Targets;Sep2011, Vol. 12 Issue 10, p1467 

    The perception that Crohn's disease is a more severe process than ulcerative colitis, led to the initial development of a majority drugs, and testing of treatment strategies, in the former. In the absence of similar studies in ulcerative colitis, information of Crohn's disease studies may help...

  • Transplacental Transfer of Immunosuppressants and Biologics Used for the Treatment of Inflammatory Bowel Disease. Chaparro, María; Gisbert, Javier P. // Current Pharmaceutical Biotechnology;May2011, Vol. 12 Issue 5, p765 

    No abstract available.

  • Sulfasalazine. Peppercorn, Mark A. // Annals of Internal Medicine;Sep84, Vol. 101 Issue 3, p377 

    Discusses sulfasalazine, a drug that is useful in the treatment of active ulcerative colitis as well as in preventing relapses of the disease in remission. Uncertainty about the mechanism of action of the drug; Agents with possible interaction with sulfasalazine; One limitation of the use of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics